Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CS 670; DW-330; DW-330SR; Pelubi; Pelubiprofen sustained release; RS 2131

Latest Information Update: 29 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sankyo
  • Developer Daewon Pharmaceutical; Sankyo
  • Class Analgesics; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Back pain; Osteoarthritis
  • Phase III Acute pain; Fever
  • No development reported Musculoskeletal pain; Rheumatoid arthritis
  • Discontinued Rheumatic disorders

Most Recent Events

  • 25 Mar 2019 Phase-III clinical trials in Acute pain in South Korea (PO, Controlled release) (NCT03874247)
  • 28 Mar 2018 No development reported - Phase-I for Musculoskeletal pain (In volunteers) in South Korea (PO)
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Musculoskeletal-pain(In volunteers) in South Korea (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top